Senior Vice President, Clinical Development

The Impact You'll Make

Recursion is seeking an accomplished clinical development leader to serve as Senior Vice President, Clinical Development. This is a senior operational and strategic role responsible for driving the clinical execution of the company's differentiated pipeline across oncology and rare disease, reporting directly to the Chief Medical Officer.

The SVP will serve as the primary architect of clinical development strategy at the program level, translating scientific vision into rigorous, efficiently executed trials that generate compelling data packages to support regulatory advancement and eventual approval. The SVP will lead a team of clinical scientists and medical directors, and cross-functional partners spanning biostatistics, clinical operations, regulatory affairs, and translational medicine.

In this role, you will:

• Lead the clinical strategy, design, and execution of oncology and rare disease programs.
• Define and execute clinical development strategy for assigned programs, including study design, endpoint selection, patient population strategy, and regulatory pathway.
• Lead the design, initiation, and oversight of early and late-stage clinical trials across oncology and rare disease indications.
• Partner with the ClinTech organization to embed clin tech within clinical development, applying AI-assisted protocol design, digital enrollment tools, and advanced analytics.
• Provide direct leadership and mentorship to a team of clinical development professionals including medical directors, clinical scientists, and program leads.
• Partner closely with Regulatory Affairs to lead FDA and international agency interactions, guide IND strategy, and support clinical sections of regulatory submissions.
• Collaborate with Clinical Operations to ensure trials are delivered on time, on budget, and to the highest quality standards.
• Integrate with Translational Medicine and Biostatistics to develop biomarker strategies, patient selection criteria, and adaptive trial designs.
• Oversee clinical safety monitoring, adverse event review, risk management and interactions with Independent Data Monitoring Committees.
• Contribute to portfolio prioritization decisions and resource allocation discussions with the CMO and executive team.
• Represent the company externally at scientific conferences, advisory boards, investigator meetings, and key opinion leader engagements.
• Support business development due diligence, partnership discussions, and potential in-licensing evaluations.
• Contribute clinical content for investor communications, including earnings calls, KOL events, and R&D days.

The Experience You'll Need

• 15 or more years of clinical development experience, with substantial time spent in oncology, rare disease, immunology or precision medicine in the biotechnology or pharmaceutical industry.
• MD, MD/PhD with specialization in oncology, hematology, rare disease, immunology or a related biomedical discipline.
• Demonstrated experience leading Phase 1 and Phase 1/2 clinical trials for novel mechanisms, including dose-escalation studies and biomarker-selected populations; direct accountability for IND filings and clinical development plans is required.
• Strong track record of cross-functional program leadership, with experience managing and developing teams of clinical scientists and medical directors.
• Experience working in or comfort operating within a TechBio, data science-forward, or AI-enabled drug development environment.
• Direct experience engaging with FDA and other regulatory agencies is required.
• Proven ability to operate with scientific rigor and operational discipline in a resource-constrained, clinical-stage company; experience managing development timelines and budgets is required.
• Strong scientific acumen in small molecule drug development, kinase biology, oncology mechanisms of action, or rare disease pathophysiology.
• Exceptional communication and leadership skills, with the ability to represent the organization credibly to regulators, investigators, and key opinion leaders.
• Experience working in a publicly traded company with exposure to investor-facing communications is preferred.
• Strategic mindset balanced with a hands-on operational orientation.